CAMRELIZUMAB

Clinical trials for CAMRELIZUMAB explained in plain language.

Never miss a new study

Get alerted when new CAMRELIZUMAB trials appear

Sign up with your email to follow new studies for CAMRELIZUMAB, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New combo therapy aims to slow advanced liver cancer

Disease control Recruiting now

This study tests whether adding a targeted drug (apatinib) and an immunotherapy (camrelizumab) to a standard liver cancer treatment (TACE) can better control cancer growth in people whose liver cancer cannot be removed by surgery. About 101 adults with intermediate or advanced li…

Matched conditions: CAMRELIZUMAB

Phase: PHASE3 • Sponsor: Guohui Xu • Aim: Disease control

Last updated Apr 30, 2026 15:51 UTC

CAMRELIZUMAB

Get alerted when new CAMRELIZUMAB trials appear

New combo therapy aims to slow advanced liver cancer